By: H.L., STA
The Swiss pharma giant Novartis continued to invest in its R&D and production capacities in Slovenia through its subsidiaries Lek, Sandoz and Novartis Pharma Services last year.
Despite the Covid-19 pandemic, the company said it had invested EUR 204 million in the country as part of its efforts to expand its R&D and production facilities in line with its plan to transform from a generics to an innovative pharmaceutical company.